These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

847 related articles for article (PubMed ID: 16601285)

  • 21. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
    Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
    Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
    Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
    Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Melatonin and prostate cancer cell proliferation: interplay with castration, epidermal growth factor, and androgen sensitivity.
    Siu SW; Lau KW; Tam PC; Shiu SY
    Prostate; 2002 Jul; 52(2):106-22. PubMed ID: 12111702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
    Pang B; Zhang H; Wang J; Chen WZ; Li SH; Shi QG; Liang RX; Xie BX; Wu RQ; Qian XL; Yu L; Li QM; Huang CF; Zhou JG
    Prostate; 2009 Aug; 69(11):1176-87. PubMed ID: 19415690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of basal cell keratins in human prostate cancer metastases and cell lines.
    van Leenders GJ; Aalders TW; Hulsbergen-van de Kaa CA; Ruiter DJ; Schalken JA
    J Pathol; 2001 Dec; 195(5):563-70. PubMed ID: 11745692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
    Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
    Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype.
    Zelivianski S; Verni M; Moore C; Kondrikov D; Taylor R; Lin MF
    Biochim Biophys Acta; 2001 May; 1539(1-2):28-43. PubMed ID: 11389966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
    Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
    Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
    Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer.
    Jennbacken K; Tesan T; Wang W; Gustavsson H; Damber JE; Welén K
    Endocr Relat Cancer; 2010 Jun; 17(2):469-79. PubMed ID: 20233707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status.
    Bonkhoff H
    Prostate Suppl; 1998; 8():18-22. PubMed ID: 9690659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo.
    Burchardt T; Burchardt M; Chen MW; Cao Y; de la Taille A; Shabsigh A; Hayek O; Dorai T; Buttyan R
    J Urol; 1999 Nov; 162(5):1800-5. PubMed ID: 10524938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line.
    Lee SO; Dutt SS; Nadiminty N; Pinder E; Liao H; Gao AC
    Prostate; 2007 Sep; 67(12):1293-300. PubMed ID: 17626246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.
    Gao J; Arnold JT; Isaacs JT
    Cancer Res; 2001 Jul; 61(13):5038-44. PubMed ID: 11431338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
    Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS
    Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
    Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
    Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications.
    Theodoropoulos VE; Tsigka A; Mihalopoulou A; Tsoukala V; Lazaris AC; Patsouris E; Ghikonti I
    Urology; 2005 Oct; 66(4):897-902. PubMed ID: 16230178
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model.
    Bonkhoff H; Remberger K
    Prostate; 1996 Feb; 28(2):98-106. PubMed ID: 8604398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
    Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 43.